The epidemic of cardiovascular disease (CVD)is a global phenomenon,and the morbidity is increasing rapidly in China.The loss of cardiomyocytes has not been solved yet ,which is the critical issue of CVD.And stem cell transplantation may be a new potential therapy.The therapeutic potential of c-kit + CSCs in cardiac diseases has been proved by plentiful preclinical and clinical studies.But ,for the absence of direct and sufficient evidence that either endogenous or exogenous adult c-kit + CSCs differenti-ate into a relevant number of mature functional myocytes,the therapeutic mechanism is still controversial. Meanwhile,the clinical application of c-kit + CSCs is still facing a number of issues,such as the optimal delivery and source of cells,the proper number of cells and the regulation of cell defferentiation.